Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma
Abstract Glioblastoma (GBM) is the most common primary central nervous system tumor, whose prognosis remains poor under the sequential standard of care, such as neurosurgery followed by concurrent temozolomide radiochemotherapy and adjuvant temozolomide chemotherapy in the presence or absence of tum...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Cancer Innovation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cai2.59 |